MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 599100 | Name: Bufezolac

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bufezolac is a bioactive chemical.

Chemical Structure

Bufezolac
Bufezolac
CAS#50270-32-1

Theoretical Analysis

MedKoo Cat#: 599100

Name: Bufezolac

CAS#: 50270-32-1

Chemical Formula: C21H22N2O2

Exact Mass: 334.1681

Molecular Weight: 334.41

Elemental Analysis: C, 75.42; H, 6.63; N, 8.38; O, 9.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Bufezolac; Bufezolacum; LM 22070; LM-22070; LM22070;
IUPAC/Chemical Name
2-(1-isobutyl-3,4-diphenyl-1H-pyrazol-5-yl)acetic acid
InChi Key
JBJASTVVFKIZBG-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H22N2O2/c1-15(2)14-23-18(13-19(24)25)20(16-9-5-3-6-10-16)21(22-23)17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3,(H,24,25)
SMILES Code
O=C(O)CC1=C(C2=CC=CC=C2)C(C3=CC=CC=C3)=NN1CC(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 334.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Miao L, Shiraishi R, Fujise T, Kuroki T, Kakimoto T, Sakata Y, Takashima T, Iwakiri R, Fujimoto K, Shi R, Li X. Chemopreventive effect of mofezolac on beef tallow diet/azoxymethane-induced colon carcinogenesis in rats. Hepatogastroenterology. 2011 Jan-Feb;58(105):81-8. PubMed PMID: 21510291. 2: Niho N, Kitamura T, Takahashi M, Mutoh M, Sato H, Matsuura M, Sugimura T, Wakabayashi K. Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac. Cancer Sci. 2006 Oct;97(10):1011-4. PubMed PMID: 16984374. 3: Kitamura T, Kawamori T, Uchiya N, Itoh M, Noda T, Matsuura M, Sugimura T, Wakabayashi K. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis. 2002 Sep;23(9):1463-6. PubMed PMID: 12189188. 4: Goto K, Ochi H, Yasunaga Y, Matsuyuki H, Imayoshi T, Kusuhara H, Okumoto T. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Prostaglandins Other Lipid Mediat. 1998 Jul;56(4):245-54. PubMed PMID: 9777656. 5: Takemoto M, Matsuo K, Katoh S, Yoshida R. [Antigenicity test of mofezolac (N-22)]. J Toxicol Sci. 1990 Jun;15 Suppl 2:261-8. Japanese. PubMed PMID: 2231794. 6: Shimpo K, Takeuchi M, Okazaki S, Kiguchi M, Hashimoto Y, Aoki Y, Kuwata M, Yamashita K. [Three-month oral subacute toxicity study of mofezolac (N-22) in rats]. J Toxicol Sci. 1990 Jun;15 Suppl 2:11-41. Japanese. PubMed PMID: 2231786. 7: Ono N, Yamamoto N, Sunami A, Yamasaki Y, Miyake H. [Pharmacological profile of mofezolac, a new non-steroidal analgesic anti-inflammatory drug]. Nihon Yakurigaku Zasshi. 1990 Feb;95(2):63-81. Japanese. PubMed PMID: 2109726. 8: Kusuhara H, Matsuyuki H, Okumoto T. Effects of nonsteroidal anti-inflammatory drugs on interleukin-1 receptor antagonist production in cultured human peripheral blood mononuclear cells. Prostaglandins. 1997 Nov;54(5):795-804. PubMed PMID: 9491209. 9: Ohuchida A, Furukawa A. Mutagenicity tests of mofezolac (N-22). J Toxicol Sci. 1990 Jun;15 Suppl 2:239-51. PubMed PMID: 2231792. 10: Satoh K, Yamamoto N, Kuwasaki E, Ichiki T, Sone H, Kodama R, Kuwata M, Yamashita K. Acute toxicity tests of mofezolac (N-22) in mice and rats. J Toxicol Sci. 1990 Jun;15 Suppl 2:1-9. PubMed PMID: 2231785. 11: Shimpo K, Takeuchi M, Kiguchi M, Iwata M, Nasu Y, Yada H, Yamashita K. [Three-month subacute oral toxicity study of mofezolac (N-22) in dogs]. J Toxicol Sci. 1990 Jun;15 Suppl 2:43-76. Japanese. PubMed PMID: 2231795. 12: Toteno I, Haguro S, Furukawa S, Morinaga T, Morino K, Fujii S, Yamakita O. [Reproductive and developmental toxicity study of mofezolac (N-22) (2)--Study by oral administration of N-22 during the period of fetal organogenesis in rats]. J Toxicol Sci. 1990 Jun;15 Suppl 2:165-208. Japanese. PubMed PMID: 2231789. 13: Satoh K, Furukawa H, Nasu Y, Sone H, Ichiki T, Kodama R, Kuwata M, Yamashita K. [Fifty two-week chronic oral toxicity study of mofezolac (N-22) in rats]. J Toxicol Sci. 1990 Jun;15 Suppl 2:77-109. Japanese. PubMed PMID: 2231796. 14: Yamakita O, Koida M, Shinomiya M, Katayama S, Ikebuchi K, Yoshida R. [Reproductive and developmental toxicity study of mofezolac (N-22) (4)--Study by oral administration of N-22 during the perinatal and lactation periods in rats]. J Toxicol Sci. 1990 Jun;15 Suppl 2:219-37. Japanese. PubMed PMID: 2231791. 15: Ohkubo M, Katsuta T, Masunaga A, Araki E, Ichiki T, Kodama R, Yamashita K. [Fifty two-week chronic oral toxicity study of mofezolac (N-22) in beagle dogs]. J Toxicol Sci. 1990 Jun;15 Suppl 2:111-49. Japanese. PubMed PMID: 2231787. 16: Ohuchida A, Furukawa A. Micronucleus test of mofezolac (N-22). J Toxicol Sci. 1990 Jun;15 Suppl 2:253-60. PubMed PMID: 2231793. 17: Fuchigami K, Otsuka T, Sameshima K, Matsunaga K, Kodama R, Yamakita O. [Reproductive and developmental toxicity study of mofezolac (N-22) (3)--Teratogenicity study in rabbits by oral administration]. J Toxicol Sci. 1990 Jun;15 Suppl 2:209-18. Japanese. PubMed PMID: 2231790. 18: Onodera M, Horiuchi Y, Nakahama K, Muneta T, Mano Y, Morita I. Induction of cyclooxygenase-1 in cultured synovial cells isolated from rheumatoid arthritis patients. Inflamm Res. 2004 Jun;53(6):217-22. Epub 2004 May 12. PubMed PMID: 15167967. 19: Yamakita O, Koida M, Shinomiya M, Katayama S, Ikebuchi K, Yoshida R. [Reproductive and developmental toxicity study of mofezolac (N-22) (1)--Study by oral administration of N-22 prior to and early stages of pregnancy in rats]. J Toxicol Sci. 1990 Jun;15 Suppl 2:151-63. Japanese. PubMed PMID: 2231788. 20: Kitamura T, Itoh M, Noda T, Matsuura M, Wakabayashi K. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int J Cancer. 2004 Apr 20;109(4):576-80. PubMed PMID: 14991580.

View History

LY-426965

LY-426965